Cannabis for Spasticity

Spasticity — involuntary muscle stiffness from MS, spinal cord injury, or stroke — is one of the best-established indications for cannabis medicine. Sativex (THC+CBD oromucosal spray) is approved in 30+ countries specifically for MS spasticity.

EMA 2010
Approval
30-50%
Spasm Reduction
Sativex
Approved Drug
Cannabis for Spasticity

How Cannabis Reduces Spasticity

Spasticity results from disrupted inhibitory signals in the central nervous system. The endocannabinoid system directly modulates GABA and glutamate neurotransmission at spinal interneurons. THC and CBD work synergistically: THC activates CB1 receptors to reduce excitatory signaling while CBD inhibits TRPV1 channels involved in central sensitization. The Sativex trials showed a 30-50% reduction in spasticity scores (NRS) versus placebo across four randomized controlled trials.

Cannabis Products for Spasticity Management

Oromucosal sprays (sublingual) provide consistent dosing critical for spasticity management. CBD+THC tinctures mimic Sativex at lower cost in legal states. Vaporized cannabis provides rapid relief for acute spasm episodes. Patients with MS typically need 8-12 sprays/day in clinical trials; home users should titrate slowly from 1-2 doses and increase weekly based on tolerance and response.

Spasticity in Specific Conditions

Multiple sclerosis patients benefit most from the combination THC+CBD formula. Spinal cord injury patients often respond well to higher THC ratios. Those with cerebral palsy, stroke, or traumatic brain injury may require different cannabinoid profiles. TBI-associated spasticity research is emerging and shows CBD may reduce neuroinflammation underlying chronic spasm patterns.

Practical Considerations

Tolerance to the psychoactive effects of THC develops rapidly, meaning most spasticity patients can take therapeutic doses with minimal intoxication after 2 weeks. Cannabis-naive patients should start very low (1-2.5mg THC) and increase gradually. Combining cannabis with existing antispasmodics like baclofen requires medical supervision due to additive CNS effects. Track spasticity using validated scales like the patient-reported NRS to document therapeutic response.

Trusted Sources

Frequently Asked Questions

Yes — Sativex (nabiximols), a cannabis-based oromucosal spray, is approved in over 30 countries for MS-related spasticity. In the US, Marinol and Syndros are FDA-approved for related indications.
CBD alone shows modest antispastic effects. Most clinical evidence supports the combination of THC+CBD as more effective than either cannabinoid alone for significant spasm reduction.
Inhaled or sublingual cannabis typically reduces acute spasm within 15-30 minutes. For ongoing spasticity management, consistent daily dosing shows cumulative benefits over 2-4 weeks.
Cannabis and baclofen can be combined but may have additive sedative effects. Always consult your neurologist before combining cannabis with existing antispasmodic medications.
MS, spinal cord injury, cerebral palsy, traumatic brain injury, and stroke are the most common causes of spasticity where cannabis evidence exists. Each condition may respond differently to cannabinoid ratios.

Related Guides